Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 20/20 | 1.00 |
| ▸ | ERBB2 | P04626 | 20/20 | 1.00 |
| ▸ | STK25 | O00506 | 2/20 | 0.78 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.78 |
| ▸ | GAK | O14976 | 2/20 | 0.78 |
| ▸ | STK17B | O94768 | 2/20 | 0.78 |
| ▸ | STK10 | O94804 | 2/20 | 0.78 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.78 |
| ▸ | ABL1 | P00519 | 2/20 | 0.78 |
| ▸ | LCK | P06239 | 2/20 | 0.78 |
| ▸ | FYN | P06241 | 2/20 | 0.78 |
| ▸ | FES | P07332 | 2/20 | 0.78 |
| ▸ | CSF1R | P07333 | 2/20 | 0.78 |
| ▸ | YES1 | P07947 | 2/20 | 0.78 |
| ▸ | LYN | P07948 | 2/20 | 0.78 |
| ▸ | MET | P08581 | 2/20 | 0.78 |
| ▸ | HCK | P08631 | 2/20 | 0.78 |
| ▸ | FGR | P09769 | 2/20 | 0.78 |
| ▸ | WEE2 | P0C1S8 | 2/20 | 0.78 |
| ▸ | SRC | P12931 | 2/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hki-357 SCHEMBL29478857 | 1.00 | EGFR (1.00) | EGFRERBB2STK25CHEK1GAK | |
| Hki-357 SCHEMBL29351355 | 1.00 | EGFR (1.00) | EGFRERBB2STK25CHEK1GAK | |
| Hki-357 SCHEMBL2203413 | 1.00 | EGFR (1.00) | EGFRERBB2STK25CHEK1GAK | |
| Hki-357 SCHEMBL29351364 | 1.00 | EGFR (1.00) | EGFRERBB2STK25CHEK1GAK | |
| Hki-357 SCHEMBL2129079 | 0.97 | EGFR (0.94) | EGFRERBB2STK25CHEK1GAK | |
| Hki-357 SCHEMBL2134691 | 0.96 | EGFR (0.93) | EGFRERBB2STK25CHEK1GAK | |
| SCHEMBL18949451 | 0.93 | EGFR (0.87) | EGFRERBB2SRCKDR | |
| SCHEMBL2204366 | 0.93 | EGFR (1.00) | EGFRERBB2STK25CHEK1GAK | |
| SCHEMBL2204372 | 0.93 | EGFR (1.00) | EGFRERBB2STK25CHEK1GAK | |
| SCHEMBL4963941 | 0.92 | EGFR (0.86) | EGFRERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2833886-A1 | SUBSTITUTED QUINOLINES AS BRUTON'S TYROSINE KINASES INHIBITORS | HangzhouDeRenYuCheng Biotechnology Ltd. (CN) | 2015-02-11 | — | — | EP | claimed |
| WO-2013152135-A1 | SUBSTITUTED QUINOLINES AS BRUTON'S TYROSINE KINASES INHIBITORS | ZHANG DAWEI (US) | 2013-10-10 | — | — | WO | claimed |
| US-20090325877-A1 | Combination Product of Receptor Tyrosine Kinase Inhibitor and Fatty Acid Synthase Inhibitor for Treating Cancer | WYETH (US) | 2009-12-31 | — | — | US | claimed |
| US-20080319011-A1 | PROTEIN TYROSINE KINASE ENZYME INHIBITORS | WYETH (US) | 2008-12-25 | — | — | US | claimed |
| US-7399865-B2 | such as (E)-N-{4-[4-(benzyloxy)-3-chloroanilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide used as antineoplastic agents, or inhibitors of the HER-2 gene or proteins and epidermal growth factor receptor enzymes | WYETH (US) | 2008-07-15 | — | — | US | claimed |
| EP-1796727-A2 | METHOD FOR THE TREATMENT OF POLYCYSTIC KIDNEY DISEASE | Wyeth a Corporation of the State of Delaware (US) | 2007-06-20 | — | — | EP | claimed |
| EP-1670473-A1 | SUBSTITUTED QUINOLINES AS PROTEIN TYROSINE KINASE ENZYME INHIBITORS | Wyeth a Corporation of the State of Delaware (US) | 2006-06-21 | — | — | EP | claimed |
| WO-2006042100-A2 | METHOD FOR THE TREATMENT OF POLYCYSTIC KIDNEY DISEASE | WYETH (US) | 2006-04-20 | — | — | WO | claimed |
| US-20060079515-A1 | Method for the treatment of polycystic kidney disease | WYETH (US) | 2006-04-13 | — | — | US | claimed |
| WO-2005034955-A1 | SUBSTITUTED QUINOLINES AS PROTEIN TYROSINE KINASE ENZYME INHIBITORS | WYETH (US) | 2005-04-21 | — | — | WO | claimed |
| WO-2005028443-A2 | PROTEIN TYROSINE KINASE ENZYME INHIBITORS | WYETH A CORPORATION OF THE STATE OF DELAWARE, USA (US) | 2005-03-31 | — | — | WO | claimed |
| US-20050059678-A1 | Protein tyrosine kinase enzyme inhibitors | WYETH (US) | 2005-03-17 | — | — | US | claimed |
| US-20220363666-A1 | TYROSINE KINASE INHIBITOR COMPOSITIONS, METHODS OF MAKING AND METHODS OF USE | BLACK DIAMOND THERAPEUTICS, INC. (US) | 2022-11-17 | — | — | US | disclosed |
| US-11034672-B1 | Tyrosine kinase inhibitor compositions, methods of making and methods of use | BLACK DIAMOND THERAPEUTICS, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| US-20210163447-A1 | TYROSINE KINASE INHIBITOR COMPOSITIONS, METHODS OF MAKING AND METHODS OF USE | BLACK DIAMOND THERAPEUTICS, INC. | 2021-06-03 | — | — | US | disclosed |
| US-9353062-B2 | Substituted quinolines as bruton's tyrosine kinases inhibitors | HANGZHOUDERENYUCHENG BIOTECHNOLOGY LTD (CN) | 2016-05-31 | — | — | US | disclosed |
| US-20060079515-A1 | Method for the treatment of polycystic kidney disease | WYETH (US) | 2006-04-13 | — | — | US | disclosed |
| WO-2005034955-A1 | SUBSTITUTED QUINOLINES AS PROTEIN TYROSINE KINASE ENZYME INHIBITORS | WYETH (US) | 2005-04-21 | — | — | WO | disclosed |
| WO-2005028443-A2 | PROTEIN TYROSINE KINASE ENZYME INHIBITORS | WYETH A CORPORATION OF THE STATE OF DELAWARE, USA (US) | 2005-03-31 | — | — | WO | disclosed |
| US-20050059678-A1 | Protein tyrosine kinase enzyme inhibitors | WYETH (US) | 2005-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080319011-A1 | PROTEIN TYROSINE KINASE ENZYME INHIBITORS | ABL1, ERBB2, RET | EGFR 6/4885ERBB2 2/4885STK25 155/4885 |
| US-20060079515-A1 | Method for the treatment of polycystic kidney disease | ERBB2, PKD2, EGFR | EGFR 3/4885ERBB2 1/4885STK25 85/4885 |
| US-11034672-B1 | Tyrosine kinase inhibitor compositions, methods of making and methods of use | ERBB2, ERBB3, EGFR | EGFR 3/4885ERBB2 1/4885STK25 223/4885 |
| US-20050059678-A1 | Protein tyrosine kinase enzyme inhibitors | ABL1, ERBB2, RET | EGFR 6/4885ERBB2 2/4885STK25 155/4885 |
| US-20220363666-A1 | TYROSINE KINASE INHIBITOR COMPOSITIONS, METHODS OF MAKING AND METHODS OF USE | ERBB2, ERBB3, EGFR | EGFR 3/4885ERBB2 1/4885STK25 223/4885 |
| US-20090325877-A1 | Combination Product of Receptor Tyrosine Kinase Inhibitor and Fatty Acid Synthase Inhibitor for Treating Cancer | FASN, FRS2, FGFR1 | EGFR 20/4885ERBB2 8/4885STK25 91/4885 |
| US-20210163447-A1 | TYROSINE KINASE INHIBITOR COMPOSITIONS, METHODS OF MAKING AND METHODS OF USE | ERBB2, ERBB3, EGFR | EGFR 3/4885ERBB2 1/4885STK25 223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.